Navigation Links
Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that lumiracoxib will be approved for sale in the US or any other additional markets, or for any additional indications. Neither can there be any guarantee that lumiracoxib will reach any particular level of sales. In particular, management's expectations regarding lumiracoxib could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the public debate and regulatory activity regarding COX-2 inhibitors like lumiracoxib; unexpected clinical trial results, including additional analysis of existing clinical data and new clinical data; government, industry, and general public pricing pressures; competition in general; Novartis' ability to obtain or maintain patent or other proprietary intellectual property protection; as well as other risk factors discussed in Novartis AG's Form 20-F filed with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceu
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inc. (NASDAQ: QCOR ) today announced ... to its Board of Directors.  Dr. Whitcup is ... Chief Scientific Officer at Allergan, Inc.  In that ... research and development organization, including medical affairs, drug ...
... Feb. 16, 2012 OPKO Health, Inc. and ChromaDex ... a strategic alliance pursuant to which ChromaDex has licensed ... health care technologies for distribution and business development throughout ... commercialized are BluScience™ ( www.bluscience.com ), ChromaDex,s ...
Cached Medicine Technology:Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 2Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 3Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors 4OPKO Health, Inc. Invests in ChromaDex® Corp. 2OPKO Health, Inc. Invests in ChromaDex® Corp. 3OPKO Health, Inc. Invests in ChromaDex® Corp. 4OPKO Health, Inc. Invests in ChromaDex® Corp. 5
(Date:4/18/2014)... LEXINGTON, Ky. (April 21, 2014) -- A group ... of Medicine and the Sanders-Brown Center on Aging ... on depression and neuropsychological function in Parkinson,s disease ... Psychiatry Research , the study, which assessed cognitive ... found that the dopamine replacement therapy commonly used ...
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... Alan Mozes HealthDay Reporter , MONDAY, Sept. 19 ... common, non-infectious diseases -- cancer, diabetes, heart disease, lung disease ... million in treatment costs and lost wages. ... Burden of Non-communicable Diseases," released by the World Economic Forum ...
... pioneered a new combination treatment for prostate cancer. The ... will now be tested for efficacy in a second phase. ... and aggressive form of prostate cancer which has spread to ... developed. It combines traditional chemotherapy treatments with two doses ...
... Massachusetts health care reform designed to bolster employer-based insurance ... unable to afford it, the uninsured in Massachusetts remain ... by researchers at Harvard Medical School just published online ... The 2006 comprehensive health care reform was designed ...
... 17 (HealthDay News) -- ,Paralyzed veterans who learned to ... new study suggests. Researchers brought 10 paralyzed veterans ... May for a four-day scuba certification course. Before ... psychological tests, measuring muscle spasticity, motor control and sensitivity ...
... 16 (HealthDay News) -- People who carry a certain ... a lower five-year survival rate after coronary artery bypass ... to better treat and ensure the survival of these ... from Duke University Medical Center in Durham, N.C. ...
... September 16, 2011 Researchers have shown for the first ... by binding to and rendering inert protein p53, a known ... Texas Medical Branch may lead to treatments for a range ... appears in the current print issue of the Journal ...
Cached Medicine News:Health News:Global Toll of 'Non-Communicable Diseases' -- $47 Trillion by 2030 2Health News:Global Toll of 'Non-Communicable Diseases' -- $47 Trillion by 2030 3Health News:Global Toll of 'Non-Communicable Diseases' -- $47 Trillion by 2030 4Health News:Queen's pioneers prostate cancer breakthrough 2Health News:Uninsured patients in Mass. still mainly the working poor, despite state's health reform 2Health News:Uninsured patients in Mass. still mainly the working poor, despite state's health reform 3Health News:Scuba Diving May Help Paralyzed Vets 2Health News:Gene Variant May Raise Death Risk After Heart Bypass 2Health News:Researchers identify potential molecular target to prevent growth of cancer cells 2
... can code the charge while completing a chart ... away from office, both directly feeding the charge ... Encounter Form/Superbill, data entry can be done with ... payments are posted by reflecting open item charges, ...
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... that a second mirror adds, then you may ... features the same 1.5x magnification as the G-1 ... and 64 respectively. Available in standard (flange) or ... "Flanged" model for laser use. Provides ...
... The AFX (Air Fluid ... image lens designed for use ... addition to its use as ... lens, the low profile and ...
Medicine Products: